文献库 文献相关信息

题目:
Recurrent SKIL-activating rearrangements in ETS-negative prostate cancer.
作者:
Annala(Matti),Kivinummi(Kati),Tuominen(Joonas),Karakurt(Serdar),Granberg(Kirsi),Latonen(Leena),Ylipää(Antti),Sjöblom(Liisa),Ruusuvuori(Pekka),Saramäki(Outi),Kaukoniemi(Kirsi M),Yli-Harja(Olli),Vessella(Robert L),Tammela(Teuvo L J),Zhang(Wei),Visakorpi(Tapio),Nykter(Matti)
状态:
发布时间2015-04-08 , 更新时间 2016-10-19
期刊:
Oncotarget
摘要:
Prostate cancer is the third most common cause of male cancer death in developed countries, and one of the most comprehensively characterized human cancers. Roughly 60% of prostate cancers harbor gene fusions that juxtapose ETS-family transcription factors with androgen regulated promoters. A second subtype, characterized by SPINK1 overexpression, accounts for 15% of prostate cancers. Here we report the discovery of a new prostate cancer subtype characterized by rearrangements juxtaposing the SMAD inhibitor SKIL with androgen regulated promoters, leading to increased SKIL expression. SKIL fusions were found in 6 of 540 (1.1%) prostate cancers and 1 of 27 (3.7%) cell lines and xenografts. 6 of 7 SKIL-positive cancers were negative for ETS overexpression, suggesting mutual exclusivity with ETS fusions. SKIL knockdown led to growth arrest in PC-3 and LNCaP cell line models of prostate cancer, and its overexpression led to increased invasiveness in RWPE-1 cells. The role of SKIL as a prostate cancer oncogene lends support to recent studies on the role of TGF-β signaling as a rate-limiting step in prostate cancer progression. Our findings highlight SKIL as an oncogene and potential therapeutic target in 1-2% of prostate cancers, amounting to an estimated 10,000 cancer diagnoses per year worldwide.
语言:
eng
DOI:
10.18632/oncotarget.3359

联系方式

山东省济南市章丘区文博路2号 齐鲁师范学院 genelibs生信实验室

山东省济南市高新区舜华路750号大学科技园北区F座4单元2楼

电话: 0531-88819269

E-mail: product@genelibs.com

微信公众号

关注微信订阅号,实时查看信息,关注医学生物学动态。